Details of Host Protein-DME Interaction (HOSPPI)

General Information of Drug-Metabolizing Enzyme (DME ID: DME1042)
DME Name Beta-glucuronidase (uidA), Lactobacillus sakei DME Info
UniProt ID
A0A2A5L2J1_LACRH
EC Number    EC: 3.2.1.31     (Click to Show/Hide the Complete EC Tree)
Hydrolases
Glycosylase
O/S-glycosyl compound glycosidase
EC: 3.2.1.31
Lineage    Species: Lactobacillus sakei     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Bacteria
Phylum: Firmicutes
Class: Bacilli
Order: Lactobacillales
Family: Lactobacillaceae
Genus: Lactobacillus
Species: Lactobacillus sakei
Interactome
Disease Specific Interactions between Host Protein and DME (HOSPPI)
      Drug co-metabolism
               Cometabolized drug: Erythromycin stearate Click to Show/Hide the Full List of HOSPPI:        7 HOSPPI
                            Cytochrome P450 1A1 (CYP1A1) Click to Show/Hide the Cometabolization Info
DME ID DME0006 DME Info
Uniprot ID
CP1A1_HUMAN
Interaction Name CYP1A1-uidA interaction [1], [2], [3]
Description The interaction, between human Cytochrome P450 1A1 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 1A2 (CYP1A2) Click to Show/Hide the Cometabolization Info
DME ID DME0003 DME Info
Uniprot ID
CP1A2_HUMAN
Interaction Name CYP1A2-uidA interaction [1], [2], [4]
Description The interaction, between human Cytochrome P450 1A2 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 1B1 (CYP1B1) Click to Show/Hide the Cometabolization Info
DME ID DME0023 DME Info
Uniprot ID
CP1B1_HUMAN
Interaction Name CYP1B1-uidA interaction [1], [2], [3]
Description The interaction, between human Cytochrome P450 1B1 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A4 (CYP3A4) Click to Show/Hide the Cometabolization Info
DME ID DME0001 DME Info
Uniprot ID
CP3A4_HUMAN
Interaction Name CYP3A4-uidA interaction [1], [2], [5]
Description The interaction, between human Cytochrome P450 3A4 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A5 (CYP3A5) Click to Show/Hide the Cometabolization Info
DME ID DME0012 DME Info
Uniprot ID
CP3A5_HUMAN
Interaction Name CYP3A5-uidA interaction [1], [2], [6]
Description The interaction, between human Cytochrome P450 3A5 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A7 (CYP3A7) Click to Show/Hide the Cometabolization Info
DME ID DME0015 DME Info
Uniprot ID
CP3A7_HUMAN
Interaction Name CYP3A7-uidA interaction [1], [2], [7]
Description The interaction, between human Cytochrome P450 3A7 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Docosahexaenoic acid omega-hydroxylase (CYP4F11) Click to Show/Hide the Cometabolization Info
DME ID DME0616 DME Info
Uniprot ID
CP4FB_HUMAN
Interaction Name CYP4F11-uidA interaction [1], [2], [8]
Description The interaction, between human Docosahexaenoic acid omega-hydroxylase and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
References
1 Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
2 Degradation of various insecticides in cooked eggs during in vitro human digestion. Environ Pollut. 2018 Dec;243(Pt A):437-443.
3 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
4 Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
5 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
6 Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
7 Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
8 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.